<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532764</url>
  </required_header>
  <id_info>
    <org_study_id>PQ-010-001</org_study_id>
    <nct_id>NCT02532764</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients</brief_title>
  <official_title>Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProQR Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProQR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled study of single and multiple ascending doses
      of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and to determine the
      pharmacokinetics of QR-010 administered via inhalation in adult homozygous for ΔF508 Cystic
      Fibrosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 14, 2017</completion_date>
  <primary_completion_date type="Actual">September 14, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Subjects Experiencing Treatment Emergent Adverse Events From Baseline Through End of Study</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Number of subjects experiencing at least one treatment emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Treatment Emergent Adverse Events From Baseline Through End of Study</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Assessment of severity of treatment emergent adverse events (TEAEs).
Severity is graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Modified for CF (CTCAE v4.03). For events not present in this listing the following grading was applied:
Mild: Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Moderate: Minimal, local, or noninvasive intervention indicated; discomfort sufficient to reduce or interfere with daily activities; Severe: Medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization may be indicated; disabling; limits self-care with significant interference with daily activities; incapacitating with inability to perform self care activities of daily living; Life-threatening: Urgent intervention indicated; immediate risk of death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Subjects Experiencing Dose-Limiting Toxicities (DLT) in Each Dose Cohort From Baseline Through End of Study Visit.</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>DLT's were defined as an allergic reaction, acute bronchospasm or acute AEs of interest requiring (immediate) medical intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Abnormalities Reported Regarding Laboratory Parameters, Vital Signs, ECG, Spirometry, and Physical Findings.</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Number of subjects experiencing at least one abnormality for the categories laboratory parameters, vital signs, ECG, spirometry and physical findings that were reported as treatment emergent adverse event with a relationship to study drug as either possibly, probably or definitely.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Cmax: QR-010 maximum serum concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Serum Concentration</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Tmax: Time to Cmax of QR-010 serum concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (T1/2)</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>The terminal elimination half-life will be estimated by non-linear regression analysis of the terminal elimination slope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve to Final Sample [AUC(0-last)]</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>Area under the curve to the final sample with a concentration greater than lower limit of quantification (LLQ) will be calculated using the linear trapezoidal method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve to Infinity [AUC(0-∞)]</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>AUC0-∞: Area under the curve to infinity will be calculated based on the last observed concentration Clast(obs) using formula: AUC0-∞=AUClast+Clast(obs)/λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Clearance (CL)</measure>
    <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
    <description>CL: Serum clearance will be estimated using the formula: CL = Dose/AUC0-∞.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change From Baseline in CFQ-R RSS</measure>
    <time_frame>Day 15, Day 33, Day 54</time_frame>
    <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS). A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change From Baseline in CFQ-R RSS as Compared to Placebo</measure>
    <time_frame>Day 15, Day 33, Day 54</time_frame>
    <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change From Baseline in CFQ-R RSS (Subgroup ppFEV1 &lt;90% at Baseline)</measure>
    <time_frame>Day 15, Day 33, Day 54</time_frame>
    <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change From Baseline in CFQ-R RSS as Compared to Placebo (Subgroup ppFEV1 &lt;90% at Baseline)</measure>
    <time_frame>Day 15, Day 33, Day 54</time_frame>
    <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''difference vs placebo in adjusted mean change from baseline'' values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change From Baseline in ppFEV1</measure>
    <time_frame>Day 15, Day 33, Day 54</time_frame>
    <description>Exploratory efficacy parameter, as measured by spirometry, and expressed in percent predicted FEV1 (ppFEV1). Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change From Baseline in ppFEV1 as Compared to Placebo</measure>
    <time_frame>Day 15, Day 33, Day 54</time_frame>
    <description>Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1 (ppFEV1). Mean values reported refer to''difference vs placebo in adjusted mean change from baseline'' values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change From Baseline in ppFEV1 (Subgroup ppFEV1 &lt;90% at Baseline)</measure>
    <time_frame>Day 15, Day 33, Day 54</time_frame>
    <description>Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change From Baseline in ppFEV1 as Compared to Placebo (Subgroup ppFEV1 &lt;90% at Baseline)</measure>
    <time_frame>Day 15, Day 33, Day 54</time_frame>
    <description>Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1. Mean values reported refer to ''difference vs placebo in adjusted mean change from baseline'' values.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>QR-010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QR-010 administered via inhalation either as a single dose or three times weekly for four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) administered via inhalation either as a single dose or three times weekly for four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QR-010</intervention_name>
    <description>Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
    <arm_group_label>QR-010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF as defined by iontophoretic pilocarpine sweat chloride test
             (sweat chloride) of &gt; 60 mmol/L

          -  Confirmation of CFTR gene mutations homozygous for the ΔF508 mutation

          -  Body mass index (BMI) ≥ 17 kg/m2

          -  Non-smoking for a minimum of two years

          -  FEV1 ≥70% of predicted normal for age, gender, and height, at Screening

          -  Stable lung function

          -  Adequate hepatic and renal function

        Exclusion Criteria:

          -  Breast‐feeding or pregnant

          -  Use of lumacaftor or ivacaftor

          -  Use of any investigational drug or device

          -  History of lung transplantation

          -  Hemoptysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Elborn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trust and Queen's University Belfast</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California USC - Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>940304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>01090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>03000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary (Health Sciences Centre)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Motol University Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cystic Fibrosis Center Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>02100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HGRL Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker- Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munich U. Hospital, Cystic Fibrosis Center for Adults</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <results_first_submitted>December 11, 2018</results_first_submitted>
  <results_first_submitted_qc>January 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 6, 2019</results_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>ΔF508</keyword>
  <keyword>RNA therapies</keyword>
  <keyword>antisense oligonucleotide</keyword>
  <keyword>CFTR</keyword>
  <keyword>F508del</keyword>
  <keyword>CF</keyword>
  <keyword>RNA therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02532764/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02532764/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The enrollment of this clinical trial followed a staggered approach; a new SAD cohort was enrolled following review of the previous SAD cohort. The first MAD cohort opened following the review of the first two SAD cohorts. Subsequent MAD dosing cohorts were initiated following review of the corresponding supportive SAD and MAD cohorts.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>QR-010 SAD 6.25mg</title>
          <description>QR-010 administered via inhalation as a single dose. QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalation</description>
        </group>
        <group group_id="P2">
          <title>QR-010 SAD 12.5 mg</title>
          <description>QR-010 administered via inhalation as a single dose. QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalation</description>
        </group>
        <group group_id="P3">
          <title>QR-010 SAD 25 mg</title>
          <description>QR-010 administered via inhalation as a single dose. QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalation</description>
        </group>
        <group group_id="P4">
          <title>QR-010 SAD 50 mg</title>
          <description>QR-010 administered via inhalation as a single dose. QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalation</description>
        </group>
        <group group_id="P5">
          <title>Placebo SAD</title>
          <description>Placebo (normal saline) administered via inhalation as a single dose Placebo: Normal Saline</description>
        </group>
        <group group_id="P6">
          <title>QR-010 MAD 6.25</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks. QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalation.</description>
        </group>
        <group group_id="P7">
          <title>QR-010 MAD 12.5 mg</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks. QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalation.</description>
        </group>
        <group group_id="P8">
          <title>QR-010 MAD 25 mg</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks. QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalation.</description>
        </group>
        <group group_id="P9">
          <title>QR-010 MAD 50 mg</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks. QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalation.</description>
        </group>
        <group group_id="P10">
          <title>Placebo MAD</title>
          <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Single Ascending Dose (SAD) Cohorts</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Multiple Ascending Dose (MAD) Cohorst</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Met stopping criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>QR-010 SAD 6.25 mg</title>
          <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="B2">
          <title>QR-010 SAD 12.5 mg</title>
          <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="B3">
          <title>QR-010 SAD 25 mg</title>
          <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="B4">
          <title>QR-010 SAD 50 mg</title>
          <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="B5">
          <title>Placebo SAD</title>
          <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
        </group>
        <group group_id="B6">
          <title>QR-010 MAD 6.25 mg</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="B7">
          <title>QR-010 MAD 12.5 mg</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="B8">
          <title>QR-010 MAD 25 mg</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="B9">
          <title>QR-010 MAD 50 mg</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="B10">
          <title>Placebo MAD</title>
          <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="7"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="9"/>
            <count group_id="B11" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.8" spread="8.01"/>
                    <measurement group_id="B2" value="21.5" spread="2.95"/>
                    <measurement group_id="B3" value="27.2" spread="7.31"/>
                    <measurement group_id="B4" value="22.7" spread="3.88"/>
                    <measurement group_id="B5" value="24.8" spread="8.26"/>
                    <measurement group_id="B6" value="22.7" spread="2.66"/>
                    <measurement group_id="B7" value="27.7" spread="10.42"/>
                    <measurement group_id="B8" value="32.3" spread="10.63"/>
                    <measurement group_id="B9" value="23.3" spread="4.18"/>
                    <measurement group_id="B10" value="26.3" spread="6.69"/>
                    <measurement group_id="B11" value="25.6" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="9.28"/>
                    <measurement group_id="B2" value="64.8" spread="2.26"/>
                    <measurement group_id="B3" value="67.5" spread="13.00"/>
                    <measurement group_id="B4" value="57.7" spread="9.70"/>
                    <measurement group_id="B5" value="62.2" spread="6.48"/>
                    <measurement group_id="B6" value="66.8" spread="6.87"/>
                    <measurement group_id="B7" value="62.6" spread="8.97"/>
                    <measurement group_id="B8" value="67.1" spread="4.35"/>
                    <measurement group_id="B9" value="61.3" spread="13.37"/>
                    <measurement group_id="B10" value="59.6" spread="9.19"/>
                    <measurement group_id="B11" value="63.0" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.1" spread="2.54"/>
                    <measurement group_id="B2" value="24.1" spread="2.33"/>
                    <measurement group_id="B3" value="23.0" spread="2.59"/>
                    <measurement group_id="B4" value="21.5" spread="2.91"/>
                    <measurement group_id="B5" value="21.4" spread="1.73"/>
                    <measurement group_id="B6" value="23.5" spread="2.76"/>
                    <measurement group_id="B7" value="22.8" spread="2.65"/>
                    <measurement group_id="B8" value="23.6" spread="1.56"/>
                    <measurement group_id="B9" value="21.3" spread="2.86"/>
                    <measurement group_id="B10" value="20.9" spread="1.56"/>
                    <measurement group_id="B11" value="22.3" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1</title>
          <description>Lung function; forced expiratory volume in 1 second</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.24" spread="0.877"/>
                    <measurement group_id="B2" value="3.15" spread="0.666"/>
                    <measurement group_id="B3" value="3.78" spread="1.092"/>
                    <measurement group_id="B4" value="3.06" spread="0.700"/>
                    <measurement group_id="B5" value="3.64" spread="0.748"/>
                    <measurement group_id="B6" value="3.49" spread="0.590"/>
                    <measurement group_id="B7" value="3.19" spread="0.600"/>
                    <measurement group_id="B8" value="2.85" spread="0.577"/>
                    <measurement group_id="B9" value="3.40" spread="0.993"/>
                    <measurement group_id="B10" value="3.18" spread="0.778"/>
                    <measurement group_id="B11" value="3.32" spread="0.792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ppFEV1</title>
          <description>Lung function; percent predicted Forced Expiratory Volume in 1 second</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.3" spread="13.31"/>
                    <measurement group_id="B2" value="91.4" spread="19.93"/>
                    <measurement group_id="B3" value="97.3" spread="20.39"/>
                    <measurement group_id="B4" value="80.9" spread="8.99"/>
                    <measurement group_id="B5" value="91.8" spread="12.91"/>
                    <measurement group_id="B6" value="90.7" spread="14.28"/>
                    <measurement group_id="B7" value="89.0" spread="14.21"/>
                    <measurement group_id="B8" value="79.9" spread="10.14"/>
                    <measurement group_id="B9" value="84.7" spread="13.59"/>
                    <measurement group_id="B10" value="86.7" spread="11.91"/>
                    <measurement group_id="B11" value="88.8" spread="14.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Subjects Experiencing Treatment Emergent Adverse Events From Baseline Through End of Study</title>
        <description>Number of subjects experiencing at least one treatment emergent adverse events (TEAEs)</description>
        <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
        <population>All subjects who received either QR-010 or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 SAD 6.25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 SAD 12.5 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 SAD 25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 SAD 50 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo SAD</title>
            <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
          </group>
          <group group_id="O6">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O7">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O8">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O9">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O10">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Subjects Experiencing Treatment Emergent Adverse Events From Baseline Through End of Study</title>
          <description>Number of subjects experiencing at least one treatment emergent adverse events (TEAEs)</description>
          <population>All subjects who received either QR-010 or placebo</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severity of Treatment Emergent Adverse Events From Baseline Through End of Study</title>
        <description>Assessment of severity of treatment emergent adverse events (TEAEs).
Severity is graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Modified for CF (CTCAE v4.03). For events not present in this listing the following grading was applied:
Mild: Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Moderate: Minimal, local, or noninvasive intervention indicated; discomfort sufficient to reduce or interfere with daily activities; Severe: Medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization may be indicated; disabling; limits self-care with significant interference with daily activities; incapacitating with inability to perform self care activities of daily living; Life-threatening: Urgent intervention indicated; immediate risk of death.</description>
        <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
        <population>All subjects who received either QR-010 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 SAD 6.25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 SAD 12.5 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 SAD 25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 SAD 50 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo SAD</title>
            <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
          </group>
          <group group_id="O6">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O7">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O8">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O9">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O10">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Treatment Emergent Adverse Events From Baseline Through End of Study</title>
          <description>Assessment of severity of treatment emergent adverse events (TEAEs).
Severity is graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Modified for CF (CTCAE v4.03). For events not present in this listing the following grading was applied:
Mild: Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Moderate: Minimal, local, or noninvasive intervention indicated; discomfort sufficient to reduce or interfere with daily activities; Severe: Medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization may be indicated; disabling; limits self-care with significant interference with daily activities; incapacitating with inability to perform self care activities of daily living; Life-threatening: Urgent intervention indicated; immediate risk of death.</description>
          <population>All subjects who received either QR-010 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-Threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Subjects Experiencing Dose-Limiting Toxicities (DLT) in Each Dose Cohort From Baseline Through End of Study Visit.</title>
        <description>DLT's were defined as an allergic reaction, acute bronchospasm or acute AEs of interest requiring (immediate) medical intervention.</description>
        <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
        <population>All subjects who received either QR-010 or placebo. There were no Dose Limiting Toxicities (DLTs) reported in the SAD or MAD cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 SAD 6.25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 SAD 12.5 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 SAD 25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 SAD 50 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo SAD</title>
            <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
          </group>
          <group group_id="O6">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O7">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O8">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O9">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O10">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Subjects Experiencing Dose-Limiting Toxicities (DLT) in Each Dose Cohort From Baseline Through End of Study Visit.</title>
          <description>DLT's were defined as an allergic reaction, acute bronchospasm or acute AEs of interest requiring (immediate) medical intervention.</description>
          <population>All subjects who received either QR-010 or placebo. There were no Dose Limiting Toxicities (DLTs) reported in the SAD or MAD cohorts.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Abnormalities Reported Regarding Laboratory Parameters, Vital Signs, ECG, Spirometry, and Physical Findings.</title>
        <description>Number of subjects experiencing at least one abnormality for the categories laboratory parameters, vital signs, ECG, spirometry and physical findings that were reported as treatment emergent adverse event with a relationship to study drug as either possibly, probably or definitely.</description>
        <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
        <population>All subjects who received either QR-010 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 SAD 6.25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 SAD 12.5 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 SAD 25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 SAD 50 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo SAD</title>
            <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
          </group>
          <group group_id="O6">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O7">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O8">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O9">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O10">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Abnormalities Reported Regarding Laboratory Parameters, Vital Signs, ECG, Spirometry, and Physical Findings.</title>
          <description>Number of subjects experiencing at least one abnormality for the categories laboratory parameters, vital signs, ECG, spirometry and physical findings that were reported as treatment emergent adverse event with a relationship to study drug as either possibly, probably or definitely.</description>
          <population>All subjects who received either QR-010 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>laboratory parameters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vital signs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spirometry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>physical findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Serum Concentration</title>
        <description>Cmax: QR-010 maximum serum concentrations</description>
        <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
        <population>Study population included all subjects treated either with QR-010 or placebo. Quantifiable serum concentrations are only available for the 50mg SAD and 50 mg MAD cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 SAD 6.25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 SAD 12.5 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 SAD 25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 SAD 50 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo SAD</title>
            <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
          </group>
          <group group_id="O6">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O7">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O8">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O9">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O10">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration</title>
          <description>Cmax: QR-010 maximum serum concentrations</description>
          <population>Study population included all subjects treated either with QR-010 or placebo. Quantifiable serum concentrations are only available for the 50mg SAD and 50 mg MAD cohorts.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="2.9" spread="1.2"/>
                    <measurement group_id="O9" value="4.53" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Dose 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="NA" spread="NA">for SAD cohorts, there is no Week 4, Dose 12 timepoint</measurement>
                    <measurement group_id="O9" value="3.63" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Serum Concentration</title>
        <description>Tmax: Time to Cmax of QR-010 serum concentrations.</description>
        <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
        <population>Population included all subjects treated with either QR-010 or placebo. Quantifiable serum concentrations are only available for the 50mg SAD and MAD cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 SAD 6.25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 SAD 12.5 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 SAD 25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 SAD 50 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo SAD</title>
            <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
          </group>
          <group group_id="O6">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O7">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O8">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O9">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O10">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Serum Concentration</title>
          <description>Tmax: Time to Cmax of QR-010 serum concentrations.</description>
          <population>Population included all subjects treated with either QR-010 or placebo. Quantifiable serum concentrations are only available for the 50mg SAD and MAD cohorts.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.6" lower_limit="0.5" upper_limit="2.1"/>
                    <measurement group_id="O9" value="0.5" lower_limit="0.5" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Dose 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">for SAD cohorts, there is no Week 4, Dose 12 timepoint</measurement>
                    <measurement group_id="O9" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (T1/2)</title>
        <description>The terminal elimination half-life will be estimated by non-linear regression analysis of the terminal elimination slope</description>
        <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
        <population>The terminal half-life is not reported because the %AUC (Area Under the Curve) extrapolation was too large.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 SAD 6.25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 SAD 12.5 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 SAD 25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 SAD 50 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo SAD</title>
            <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
          </group>
          <group group_id="O6">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O7">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O8">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O9">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O10">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (T1/2)</title>
          <description>The terminal elimination half-life will be estimated by non-linear regression analysis of the terminal elimination slope</description>
          <population>The terminal half-life is not reported because the %AUC (Area Under the Curve) extrapolation was too large.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve to Final Sample [AUC(0-last)]</title>
        <description>Area under the curve to the final sample with a concentration greater than lower limit of quantification (LLQ) will be calculated using the linear trapezoidal method</description>
        <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
        <population>Quantifiable serum concentrations are only available for the 50mg SAD and MAD cohort. For the PK parameters of the SAD 6.25, 12.5 and 25mg cohorts, no quantifiable serum concentrations could be measured. For the 6.25, 12.5 and 25mg MAD cohorts, no PK profiling was performed due to the large number of samples below the limit of detection.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 SAD 6.25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 SAD 12.5 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 SAD 25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 SAD 50 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo SAD</title>
            <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
          </group>
          <group group_id="O6">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O7">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O8">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O9">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O10">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve to Final Sample [AUC(0-last)]</title>
          <description>Area under the curve to the final sample with a concentration greater than lower limit of quantification (LLQ) will be calculated using the linear trapezoidal method</description>
          <population>Quantifiable serum concentrations are only available for the 50mg SAD and MAD cohort. For the PK parameters of the SAD 6.25, 12.5 and 25mg cohorts, no quantifiable serum concentrations could be measured. For the 6.25, 12.5 and 25mg MAD cohorts, no PK profiling was performed due to the large number of samples below the limit of detection.</population>
          <units>ng.hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="17.2" spread="8.2"/>
                    <measurement group_id="O9" value="19.0" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Dose 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="NA" spread="NA">for SAD cohorts, there is no Week 4, Dose 12 timepoint</measurement>
                    <measurement group_id="O9" value="17.0" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve to Infinity [AUC(0-∞)]</title>
        <description>AUC0-∞: Area under the curve to infinity will be calculated based on the last observed concentration Clast(obs) using formula: AUC0-∞=AUClast+Clast(obs)/λz</description>
        <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
        <population>The Area Under the Curve to Infinity is not reported because the %AUC extrapolation was too large</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 SAD 6.25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 SAD 12.5 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 SAD 25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 SAD 50 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo SAD</title>
            <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
          </group>
          <group group_id="O6">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O7">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O8">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O9">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O10">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve to Infinity [AUC(0-∞)]</title>
          <description>AUC0-∞: Area under the curve to infinity will be calculated based on the last observed concentration Clast(obs) using formula: AUC0-∞=AUClast+Clast(obs)/λz</description>
          <population>The Area Under the Curve to Infinity is not reported because the %AUC extrapolation was too large</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Clearance (CL)</title>
        <description>CL: Serum clearance will be estimated using the formula: CL = Dose/AUC0-∞.</description>
        <time_frame>8 Days for Single-dose cohorts; 8 weeks for Multiple-dose cohorts</time_frame>
        <population>The Serum Clearance is not reported because the %AUC extrapolation was too large.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 SAD 6.25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 SAD 12.5 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 SAD 25 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 SAD 50 mg</title>
            <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo SAD</title>
            <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
          </group>
          <group group_id="O6">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O7">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O8">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O9">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O10">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Clearance (CL)</title>
          <description>CL: Serum clearance will be estimated using the formula: CL = Dose/AUC0-∞.</description>
          <population>The Serum Clearance is not reported because the %AUC extrapolation was too large.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change From Baseline in CFQ-R RSS</title>
        <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS). A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
        <time_frame>Day 15, Day 33, Day 54</time_frame>
        <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses.
For 1 subject in the placebo group no data were available at Day 54. &quot;Mean&quot; in this table refers to &quot;Adjusted Mean&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in CFQ-R RSS</title>
          <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS). A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
          <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses.
For 1 subject in the placebo group no data were available at Day 54. &quot;Mean&quot; in this table refers to &quot;Adjusted Mean&quot;.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.13" spread="4.10"/>
                    <measurement group_id="O2" value="8.95" spread="4.12"/>
                    <measurement group_id="O3" value="7.76" spread="4.15"/>
                    <measurement group_id="O4" value="-0.80" spread="4.51"/>
                    <measurement group_id="O5" value="-5.09" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.43" spread="4.92"/>
                    <measurement group_id="O2" value="12.65" spread="4.93"/>
                    <measurement group_id="O3" value="7.76" spread="4.96"/>
                    <measurement group_id="O4" value="-3.02" spread="5.40"/>
                    <measurement group_id="O5" value="-6.48" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.24" spread="6.56"/>
                    <measurement group_id="O2" value="0.61" spread="6.57"/>
                    <measurement group_id="O3" value="5.91" spread="6.59"/>
                    <measurement group_id="O4" value="-4.13" spread="7.20"/>
                    <measurement group_id="O5" value="-10.31" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change From Baseline in CFQ-R RSS as Compared to Placebo</title>
        <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
        <time_frame>Day 15, Day 33, Day 54</time_frame>
        <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in CFQ-R RSS as Compared to Placebo</title>
          <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
          <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="5.46"/>
                    <measurement group_id="O2" value="14.03" spread="5.49"/>
                    <measurement group_id="O3" value="12.85" spread="5.55"/>
                    <measurement group_id="O4" value="4.29" spread="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.91" spread="6.53"/>
                    <measurement group_id="O2" value="19.13" spread="6.56"/>
                    <measurement group_id="O3" value="14.24" spread="6.60"/>
                    <measurement group_id="O4" value="3.46" spread="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="8.81"/>
                    <measurement group_id="O2" value="10.92" spread="8.83"/>
                    <measurement group_id="O3" value="16.22" spread="8.87"/>
                    <measurement group_id="O4" value="6.18" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline CFQ-R RSS as outcome variable and including treatment, baseline CFQ-R RSS value, time and interaction between time and treatment as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0592</p_value>
            <p_value_desc>p-values are presented for Day 33.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference vs placebo</param_type>
            <param_value>12.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>26.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline CFQ-R RSS as outcome variable and including treatment, baseline CFQ-R RSS value, time and interaction between time and treatment as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0074</p_value>
            <p_value_desc>p-values are presented for Day 33</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>difference vs placebo</param_type>
            <param_value>19.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.62</ci_lower_limit>
            <ci_upper_limit>32.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline CFQ-R RSS as outcome variable and including treatment, baseline CFQ-R RSS value, time and interaction between time and treatment as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0408</p_value>
            <p_value_desc>p-values are presented for Day 33</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>difference vs placebo</param_type>
            <param_value>14.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>27.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline CFQ-R RSS as outcome variable and including treatment, baseline CFQ-R RSS value, time and interaction between time and treatment as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6193</p_value>
            <p_value_desc>p-values are presented for Day 33</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>difference vs placebo</param_type>
            <param_value>3.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.69</ci_lower_limit>
            <ci_upper_limit>17.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change From Baseline in CFQ-R RSS (Subgroup ppFEV1 &lt;90% at Baseline)</title>
        <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
        <time_frame>Day 15, Day 33, Day 54</time_frame>
        <population>Subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses, with ppFEV1 &lt;90% at baseline.
For 1 subject in the placebo group no data were available at Day 54. &quot;Mean&quot; in this table refers to &quot;Adjusted Mean&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in CFQ-R RSS (Subgroup ppFEV1 &lt;90% at Baseline)</title>
          <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
          <population>Subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses, with ppFEV1 &lt;90% at baseline.
For 1 subject in the placebo group no data were available at Day 54. &quot;Mean&quot; in this table refers to &quot;Adjusted Mean&quot;.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.37" spread="5.51"/>
                    <measurement group_id="O2" value="8.64" spread="4.87"/>
                    <measurement group_id="O3" value="9.56" spread="4.28"/>
                    <measurement group_id="O4" value="-0.87" spread="4.79"/>
                    <measurement group_id="O5" value="-4.77" spread="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.45" spread="7.36"/>
                    <measurement group_id="O2" value="15.58" spread="6.44"/>
                    <measurement group_id="O3" value="8.44" spread="5.71"/>
                    <measurement group_id="O4" value="-0.87" spread="6.38"/>
                    <measurement group_id="O5" value="-11.72" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.37" spread="6.36"/>
                    <measurement group_id="O2" value="5.86" spread="5.59"/>
                    <measurement group_id="O3" value="7.33" spread="4.94"/>
                    <measurement group_id="O4" value="-3.65" spread="5.52"/>
                    <measurement group_id="O5" value="-6.49" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change From Baseline in CFQ-R RSS as Compared to Placebo (Subgroup ppFEV1 &lt;90% at Baseline)</title>
        <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''difference vs placebo in adjusted mean change from baseline'' values.</description>
        <time_frame>Day 15, Day 33, Day 54</time_frame>
        <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses, with ppFEV1 &lt;90% at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in CFQ-R RSS as Compared to Placebo (Subgroup ppFEV1 &lt;90% at Baseline)</title>
          <description>Patient Reported Outcome measure Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score (CFQ-R RSS).
A higher score represents a better outcome. A minimal clinically important difference (MCID) in the respiratory domain (CFQ-R RSS) has been established in stable populations as 4.0 points, and a maximum score is 100 points. Mean values reported refer to ''difference vs placebo in adjusted mean change from baseline'' values.</description>
          <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses, with ppFEV1 &lt;90% at Baseline.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="7.29"/>
                    <measurement group_id="O2" value="13.41" spread="6.95"/>
                    <measurement group_id="O3" value="14.33" spread="6.49"/>
                    <measurement group_id="O4" value="3.90" spread="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.17" spread="9.73"/>
                    <measurement group_id="O2" value="27.30" spread="9.17"/>
                    <measurement group_id="O3" value="20.16" spread="8.62"/>
                    <measurement group_id="O4" value="10.84" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="8.93"/>
                    <measurement group_id="O2" value="12.35" spread="8.58"/>
                    <measurement group_id="O3" value="13.82" spread="8.08"/>
                    <measurement group_id="O4" value="2.84" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline CFQ-R RSS as outcome variable and including treatment, baseline CFQ-R RSS value, time and interaction between time and treatment as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0321</p_value>
            <p_value_desc>p-values are presented for Day 33.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference vs placebo</param_type>
            <param_value>23.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.29</ci_lower_limit>
            <ci_upper_limit>44.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline CFQ-R RSS as outcome variable and including treatment, baseline CFQ-R RSS value, time and interaction between time and treatment as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0100</p_value>
            <p_value_desc>p-values are presented for Day 33.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference vs placebo</param_type>
            <param_value>27.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.64</ci_lower_limit>
            <ci_upper_limit>46.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline CFQ-R RSS as outcome variable and including treatment, baseline CFQ-R RSS value, time and interaction between time and treatment as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0346</p_value>
            <p_value_desc>p-values are presented for Day 33.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference vs placebo</param_type>
            <param_value>20.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.68</ci_lower_limit>
            <ci_upper_limit>38.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline CFQ-R RSS as outcome variable and including treatment, baseline CFQ-R RSS value, time and interaction between time and treatment as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2485</p_value>
            <p_value_desc>p-values are presented for Day 33.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference vs placebo</param_type>
            <param_value>10.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.47</ci_lower_limit>
            <ci_upper_limit>30.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change From Baseline in ppFEV1</title>
        <description>Exploratory efficacy parameter, as measured by spirometry, and expressed in percent predicted FEV1 (ppFEV1). Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
        <time_frame>Day 15, Day 33, Day 54</time_frame>
        <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in ppFEV1</title>
          <description>Exploratory efficacy parameter, as measured by spirometry, and expressed in percent predicted FEV1 (ppFEV1). Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
          <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses.</population>
          <units>percentage of predicted</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>(pre-dose) Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="1.96"/>
                    <measurement group_id="O2" value="2.50" spread="1.96"/>
                    <measurement group_id="O3" value="-4.03" spread="1.96"/>
                    <measurement group_id="O4" value="-1.85" spread="2.14"/>
                    <measurement group_id="O5" value="-0.83" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>(pre-dose) Day 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="2.64"/>
                    <measurement group_id="O2" value="3.22" spread="2.64"/>
                    <measurement group_id="O3" value="-0.98" spread="2.64"/>
                    <measurement group_id="O4" value="-1.39" spread="2.89"/>
                    <measurement group_id="O5" value="-0.80" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="2.40"/>
                    <measurement group_id="O2" value="0.05" spread="2.40"/>
                    <measurement group_id="O3" value="-2.17" spread="2.40"/>
                    <measurement group_id="O4" value="-3.21" spread="2.63"/>
                    <measurement group_id="O5" value="-2.70" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="2.88"/>
                    <measurement group_id="O2" value="-1.63" spread="2.88"/>
                    <measurement group_id="O3" value="0.61" spread="2.88"/>
                    <measurement group_id="O4" value="-2.43" spread="3.15"/>
                    <measurement group_id="O5" value="-2.58" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change From Baseline in ppFEV1 as Compared to Placebo</title>
        <description>Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1 (ppFEV1). Mean values reported refer to''difference vs placebo in adjusted mean change from baseline'' values.</description>
        <time_frame>Day 15, Day 33, Day 54</time_frame>
        <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in ppFEV1 as Compared to Placebo</title>
          <description>Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1 (ppFEV1). Mean values reported refer to''difference vs placebo in adjusted mean change from baseline'' values.</description>
          <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses.</population>
          <units>percentage of predicted</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="2.59"/>
                    <measurement group_id="O2" value="3.32" spread="2.59"/>
                    <measurement group_id="O3" value="-3.20" spread="2.59"/>
                    <measurement group_id="O4" value="-1.02" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="3.49"/>
                    <measurement group_id="O2" value="4.02" spread="3.49"/>
                    <measurement group_id="O3" value="-0.17" spread="3.49"/>
                    <measurement group_id="O4" value="-0.59" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="3.18"/>
                    <measurement group_id="O2" value="2.75" spread="3.18"/>
                    <measurement group_id="O3" value="0.53" spread="3.18"/>
                    <measurement group_id="O4" value="-0.51" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="3.81"/>
                    <measurement group_id="O2" value="0.96" spread="3.80"/>
                    <measurement group_id="O3" value="3.20" spread="3.81"/>
                    <measurement group_id="O4" value="0.15" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline ppFEV1 as outcome variable and including treatment, baseline ppFEV1 value, time and interaction between time and treatment as covariate</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1938</p_value>
            <p_value_desc>P-values are presented for Day 33</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>difference vs placebo</param_type>
            <param_value>4.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.30</ci_lower_limit>
            <ci_upper_limit>10.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline ppFEV1 as outcome variable and including treatment, baseline ppFEV1 value, time and interaction between time and treatment as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3943</p_value>
            <p_value_desc>P-values are presented for Day 33</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>difference vs placebo</param_type>
            <param_value>2.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.79</ci_lower_limit>
            <ci_upper_limit>9.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline ppFEV1 as outcome variable and including treatment, baseline ppFEV1 value, time and interaction between time and treatment as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8688</p_value>
            <p_value_desc>P-values are presented for Day 33</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>difference vs placebo</param_type>
            <param_value>0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.01</ci_lower_limit>
            <ci_upper_limit>7.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A mixed-model analysis was performed with repeated time measures on the change from baseline ppFEV1 as outcome variable and including treatment, baseline ppFEV1 value, time and interaction between time and treatment as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8813</p_value>
            <p_value_desc>P-values are presented for Day 33</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>difference vs placebo</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.41</ci_lower_limit>
            <ci_upper_limit>6.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change From Baseline in ppFEV1 (Subgroup ppFEV1 &lt;90% at Baseline)</title>
        <description>Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
        <time_frame>Day 15, Day 33, Day 54</time_frame>
        <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses, with ppFEV1 &lt;90% at Baseline..</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O5">
            <title>Placebo MAD</title>
            <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in ppFEV1 (Subgroup ppFEV1 &lt;90% at Baseline)</title>
          <description>Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1. Mean values reported refer to ''adjusted mean change from baseline'' values.</description>
          <population>All subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses, with ppFEV1 &lt;90% at Baseline..</population>
          <units>percentage of predicted</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="2.22"/>
                    <measurement group_id="O2" value="4.54" spread="1.92"/>
                    <measurement group_id="O3" value="-3.45" spread="1.71"/>
                    <measurement group_id="O4" value="-1.01" spread="1.91"/>
                    <measurement group_id="O5" value="-3.40" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="4.05"/>
                    <measurement group_id="O2" value="7.15" spread="3.51"/>
                    <measurement group_id="O3" value="0.89" spread="3.13"/>
                    <measurement group_id="O4" value="-0.10" spread="3.50"/>
                    <measurement group_id="O5" value="-3.76" spread="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" spread="3.16"/>
                    <measurement group_id="O2" value="3.81" spread="2.74"/>
                    <measurement group_id="O3" value="-0.68" spread="2.44"/>
                    <measurement group_id="O4" value="-0.97" spread="2.73"/>
                    <measurement group_id="O5" value="-4.18" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change From Baseline in ppFEV1 as Compared to Placebo (Subgroup ppFEV1 &lt;90% at Baseline)</title>
        <description>Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1. Mean values reported refer to ''difference vs placebo in adjusted mean change from baseline'' values.</description>
        <time_frame>Day 15, Day 33, Day 54</time_frame>
        <population>Subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses, with ppFEV1 &lt;90% at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>QR-010 MAD 6.25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O2">
            <title>QR-010 MAD 12.5 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O3">
            <title>QR-010 MAD 25 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
          <group group_id="O4">
            <title>QR-010 MAD 50 mg</title>
            <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in ppFEV1 as Compared to Placebo (Subgroup ppFEV1 &lt;90% at Baseline)</title>
          <description>Exploratory efficacy parameter, as measured by spirometry, and expresssed in percent predicted FEV1. Mean values reported refer to ''difference vs placebo in adjusted mean change from baseline'' values.</description>
          <population>Subjects treated with either QR-010 or placebo in the Multiple Ascending Dose cohorts that received at least 10 out of 12 doses, with ppFEV1 &lt;90% at Baseline.</population>
          <units>percentage of predicted</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="2.99"/>
                    <measurement group_id="O2" value="7.93" spread="2.76"/>
                    <measurement group_id="O3" value="-0.05" spread="2.59"/>
                    <measurement group_id="O4" value="2.38" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.97" spread="5.39"/>
                    <measurement group_id="O2" value="10.90" spread="4.98"/>
                    <measurement group_id="O3" value="4.65" spread="4.71"/>
                    <measurement group_id="O4" value="3.65" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.19" spread="4.22"/>
                    <measurement group_id="O2" value="7.99" spread="3.91"/>
                    <measurement group_id="O3" value="3.50" spread="3.69"/>
                    <measurement group_id="O4" value="3.21" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0301</p_value>
            <p_value_desc>P-values are presented for Day 33</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference vs placebo</param_type>
            <param_value>10.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>19.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0601</p_value>
            <p_value_desc>P-values are presented for Day 33</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference vs placebo</param_type>
            <param_value>7.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>16.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3580</p_value>
            <p_value_desc>P-values are presented for Day 33</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference vs placebo</param_type>
            <param_value>3.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.40</ci_lower_limit>
            <ci_upper_limit>11.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4224</p_value>
            <p_value_desc>P-values are presented for Day 33</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Difference vs placebo</param_type>
            <param_value>3.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.13</ci_lower_limit>
            <ci_upper_limit>11.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the SAD cohorts, from randomization up to Day 8 after dose administration. For the MAD cohorts, from randomization for at least 30 days after the last administration of the study treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>QR-010 SAD 6.25 mg</title>
          <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="E2">
          <title>QR-010 SAD 12.5 mg</title>
          <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="E3">
          <title>QR-010 SAD 25 mg</title>
          <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="E4">
          <title>QR-010 SAD 50 mg</title>
          <description>QR-010 administered via inhalation as a single dose
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="E5">
          <title>Placebo SAD</title>
          <description>Placebo (normal saline) administered via inhalation as a single dose
Placebo: Normal Saline</description>
        </group>
        <group group_id="E6">
          <title>QR-010 MAD 6.25 mg</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="E7">
          <title>QR-010 MAD 12.5 mg</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="E8">
          <title>QR-010 MAD 25 mg</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="E9">
          <title>QR-010 MAD 50 mg</title>
          <description>QR-010 administered via inhalation three times weekly for four weeks.
QR-010: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton</description>
        </group>
        <group group_id="E10">
          <title>Placebo MAD</title>
          <description>Placebo (normal saline) administered via inhalation three times weekly for four weeks.
Placebo: Normal Saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators are restricted from disclosure or results until after multicenter publication or 12 months after the completion of the Study at all participating research centers. Sponsor can review results communication prior to public release and can embargo communications regarding trial results for a period that is more than 45 days (varying per site). Sponsor may request redaction of confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Monitor</name_or_title>
      <organization>ProQR Therapeutics</organization>
      <phone>+31 6 20 183 437</phone>
      <email>clinical@proqr.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

